The global liver diseases therapeutics market size is projected to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing incidences of hepatocellular carcinoma and other chronic diseases.
Liver disease is inherited or is caused by various elements that damage the liver due to excessive usage of alcohol or the virus infection. If the disease is not timely treated, it can damage the liver that further leads to liver failure. Thus, some of the key drugs are used in the diagnosis of several types of liver diseases that include immunosuppressants, vaccines, antiviral drugs, and chemotherapy drugs. The presence of vaccination campaigns introduced by the governments and key major companies are spreading awareness about the diseases and its preventions.
For instance, the China Government spent over USD 420 million to inoculate nearly 140 million unvaccinated children in 2011. In the U.S., the Affordable Care Act was focusing on the expansion of access to diagnosis, viral hepatitis prevention, and treatment and care.
The COVID-19 pandemic directly cause to rapid surge in liver infection cases. The reason of liver injury by the COVID?19 can be driven by various factors including hypoxia, virus?induced systemic inflammation, drug-induced liver disease, and hepatic congestion. In addition, the COVID?19 adversely affected outcomes of patients with chronic liver disease and accelerated the fatality rate of the COVID patients. Hence, there is a surge in the diagnosis, treatment, and follow-up of patients with liver disease, this has positively impacted the overall market revenue.
The report on the global liver diseases therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Liver Diseases Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Products (Vaccines, Antiviral Drugs, Targeted Therapy, Immunosuppressants, Chemotherapy, Immunoglobulins, and Corticosteroids) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Astellas Pharma Inc.; Abbott Laboratories; Bristol-Mayers Squibb; GlaxoSmithKline plc.; Gilead Sciences, Inc.; F. Hoffmann-La Roche AG; Novartis International AG; Merck & Co., Inc.; Sanofi S.A.; Takeda Pharmaceuticals; Pfizer Inc.; Watson Pharmaceuticals; and Bausch Health Companies Inc. |
Based on products, the global liver diseases therapeutics market is divided into vaccines, antiviral drugs, targeted therapy, immunosuppressants, chemotherapy, immunoglobulins, and corticosteroids. The antiviral drugs segment accounted for a key share of the market in 2019 and is expected to grow at a rapid pace during the forecast period. The segment growth is attributed to increasing population with rising number of alcohol consumption, and increasing the prevalence of liver diseases. However, the chemotherapy segment is estimated to expand at a robust growth rate during the forecast period due to advancement in medical diagnosis in the field.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share in the coming years due to the wide engagement in academic and research institutes initiating medical trial studies in the region. The market of Asia Pacific, however, is expected to grow rapidly during the forecast period owing to supportive government initiatives in various countries of the region such as Japan and Australia. Moreover, favorable government policies pertaining to drug price adjustment and the development of novel drugs for the treatment of liver diseases in the region present key drivers of the market growth in Asia Pacific.
The global liver diseases therapeutics market has been segmented on the basis of
Key players competing in the global liver diseases therapeutics market are Astellas Pharma Inc.; Abbott Laboratories; Bristol-Mayers Squibb; GlaxoSmithKline plc.; Gilead Sciences, Inc.; F. Hoffmann-La Roche AG; Novartis International AG; Merck & Co., Inc.; Sanofi S.A.; Takeda Pharmaceuticals; Pfizer Inc.; Watson Pharmaceuticals; and Bausch Health Companies Inc. The main market players are continuously engaged in market development activities such as mergers and acquisitions, research and developments, investments for innovative products and collaborations. For instance, GSK declared the US FDA approval of PROMACTA for the diagnosis of thrombocytopenia in patients in November 2012.
The global liver diseases therapeutics market has been segmented on the basis of
Key players competing in the global liver diseases therapeutics market are Astellas Pharma Inc.; Abbott Laboratories; Bristol-Mayers Squibb; GlaxoSmithKline plc.; Gilead Sciences, Inc.; F. Hoffmann-La Roche AG; Novartis International AG; Merck & Co., Inc.; Sanofi S.A.; Takeda Pharmaceuticals; Pfizer Inc.; Watson Pharmaceuticals; and Bausch Health Companies Inc. The main market players are continuously engaged in market development activities such as mergers and acquisitions, research and developments, investments for innovative products and collaborations. For instance, GSK declared the US FDA approval of PROMACTA for the diagnosis of thrombocytopenia in patients in November 2012.
Some other reports from this category!